Floatz logo

Cabergoline

Pituitary Tumor

RECORDATI GROUPSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pituitary Tumor cohort.

Asset / SponsorPhaseRating
Pasireotide
RECORDATI GROUP
Phase 4BB
Dexasone
National Cancer Institute (NCI)
Phase 1CC
RG 4733
National Cancer Institute (NCI)
Phase 1C
Serostim
Federico II University
UnknownD

Same molecule, other indications

Cabergoline is also rated in:

acromegalyDormant
BB
Indicative · Phase 4
69 / 100
View asset →
Cushing disease due to pituitary adenomaActive
BB
Indicative · Phase 4
69 / 100
View asset →
ectopic ACTH secretion syndromeDormant
BB
Indicative · Phase 4
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →